For instance, recurrent mutations in cancer-relevant molecular categories in BC were identified, including p53-mediated cell cycle (TP53 and CDKN2A/2B), the RTK-RAS-PI3K pathway (PIK3CA) and epigenetic regulators (KDM6A and ARID1A), for targeted treatments [2,3]. The gene discussed is TP53; the disease is cancer.